Pioglitazone, a PPARγ agonist, enhanced the therapeutic effects of adipose tissue-derived regenerative cells on chronic myocardial infarction by stimulating adiponectin paracrine activity and M2 macrophage polarization [50]. This evidence concerns the gene ADIPOQ and myocardial infarction.